Important Safety Information for Lantus® (insulin glargine [rDNA] injection)
Do not take Lantus® if you are allergic to insulin or any of the inactive ingredients
in Lantus®.
You must test your blood sugar levels while using insulin, such as Lantus®. Do not
make any changes to your dose or type of insulin without talking to your healthcare
provider. Any change of insulin should be made cautiously and only under medical
supervision.
Do NOT dilute or mix Lantus® with any other insulin or solution. It will not
work as intended and you may lose blood sugar control, which could be serious. Lantus® must only
be used if the solution is clear and colorless with no particles visible. Do not
share needles, insulin pens or syringes with others.
The most common side effect of insulin, including Lantus®, is low blood sugar
(hypoglycemia), which may be serious. Some people may experience symptoms
such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia
can be dangerous and can cause harm to your heart or brain. It may cause unconsciousness,
seizures, or death. Other possible side effects may include injection site reactions,
including changes in fat tissue at the injection site, and allergic reactions, including
itching and rash. In rare cases, some allergic reactions may be life threatening.
Tell your doctor about other medicines and supplements you are taking because they
can change the way insulin works. Before starting Lantus®, tell your doctor about
all your medical conditions including if you have liver or kidney problems, are
pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed.
Indications and Usage for Lantus®
Prescription Lantus® is a long-acting insulin used to treat adults with type 2 diabetes
and adults and children (6 years and older) with type 1 diabetes for the control
of high blood sugar. It should be taken once a day at the same time each day to
lower blood glucose.
Do not use Lantus® to treat diabetic ketoacidosis.
Click
here for additional important information for Lantus®.
Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)
Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you are
allergic to any of the ingredients in Apidra®.
You must test your blood sugar levels while using insulin, such as Apidra®. Do not
make any changes to your dose or type of insulin without talking to your healthcare
provider. Any change of insulin should be made cautiously and only under medical
supervision. Apidra® must only be used if the solution is clear and colorless with
no particles visible. Do not share needles, insulin pens or syringes with others.
Apidra®, when given by injection under the skin, should not be mixed with insulins
other than NPH. Do not mix Apidra® with any insulin when used in the pump or for
intravenous administration. Insulin devices and needles must not be shared between
patients.
The most common side effect of insulin, including Apidra®, is low blood sugar
(hypoglycemia), which may be serious. Some people may experience symptoms
such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia
can be dangerous and can cause harm to your heart or brain. It may cause unconsciousness,
seizures, or death. Other possible side effects may include low blood potassium,
injection site reactions, such as changes in fat tissue at the injection site, and
allergic reactions, such as itching and rash. Less common, but potentially more
serious or life-threatening, is generalized allergy to insulin, including anaphylactic
reactions.
Tell your doctor about other medicines and supplements you are taking because they
can change the way insulin works. Before starting Apidra®, tell your doctor about
all your medical conditions including if you have liver or kidney problems, are
pregnant or planning to become pregnant, or are breast-feeding or planning to breast-feed.
Indications and Usage for Apidra®
Prescription Apidra® is for adults with type 2 diabetes or adults and children (4
years and older) with type 1 diabetes to improve blood sugar control. Apidra® is
usually used with a longer-acting insulin. When used as a mealtime insulin, Apidra® should
be given within 15 minutes before or within 20 minutes after starting a meal.
Click
here for additional important information for Apidra®.